Methylene blue was a fabric dye in 1876 before it became an approved emergency medicine, and Tony Huge says he and Coach Trevor were experimenting with it as a biohacking tool a decade before anyone on YouTube mentioned it. This video is his walk through the methylene blue studies: a plain-language version of the mechanism, every dose range the trials actually used, a grade for each claim from A to E, and the one risk that has kept his own dosing low for ten years.
Video: Methylene Blue Explained: What the Studies Show. Published July 31, 2026. Watch on YouTube.
What the video covers
- 00:00 What it is: A synthetic dye that stains everything blue, and one of Tony’s earliest biohacking tools.
- 00:36 Dye to medicine: Aquariums, microscope slides, malaria, and an approved use for a blood disorder.
- 01:49 The mechanism, simplified: An assembly line with four steps, and a molecule that carries the load past the slow one.
- 03:44 The dose ranges: Hospital antidote dosing, the 280 mg memory trial, malaria, the rodent curve, and the placebo oddity.
- 08:35 Grading the claims: One A, four Bs, a row of Cs, and why a single-molecule trial can miss.
- 12:00 What people report: Energy first, then brain fog, focus, mood, and one report of feeling emotionless.
- 14:13 The real risk: It is an MAOI, and serotonin syndrome is what happens when you forget that.
- 15:43 Tony’s decade: Why he started, what scared him off higher doses, and how he uses it morning and night.
- 19:04 Verdict: Medically approved, widely used, and in Tony’s view part of a future daily multivitamin.
The assembly line explanation
Tony’s complaint about most methylene blue explainers is that nobody without a biology background understands them, so he builds the mechanism from one idea. Every cell needs energy. Energy is made by passing a load down an assembly line, and when one step gets slower the whole line slows, less energy comes out, and you feel that as fatigue, slower recovery, and everything in the body running a little worse. That line is the electron transport chain, and it sits inside the mitochondria.
Methylene blue’s job is to take the load from one step, skip the sluggish one, and hand it to the next, so the chain keeps running and energy output holds up. Tony cites a Progress in Neurobiology paper describing it at low dose as an alternative electron carrier in the mitochondrial electron transport chain, increasing cytochrome oxidase activity and cerebral metabolic rate. If you only remember one slide, he says, it is that one: cells make energy by handing electrons down a chain of four steps, a slow step drops output, and methylene blue carries the electrons past it.
The dose changes what it is
This is the point Tony hammers hardest. Methylene blue becomes a different compound at different doses. The approved hospital use, for a blood disorder where hemoglobin stops carrying oxygen properly, is 1 to 2 mg per kilogram intravenously over three to five minutes, with another 1 mg per kilogram if levels have not fallen within 30 to 60 minutes, and a ceiling of 7 mg per kilogram. Tony works that through for a 100 kg man: 100 to 200 mg, with a ceiling of 700 mg, which he says is far beyond the highest biohacking dose he has ever seen. The ceiling exists because past it the drug causes the opposite of what it treats.
“The dosages being sold on the consumer market are actually the dosages that were used in the placebo.”
Tony Huge, 06:50
For cognition, the one human study is a single 280 mg oral dose, roughly 4 mg per kilogram for a 70 kg adult, in 26 participants with brain imaging, producing a 7% memory improvement. Tony calls that a very high dose by his standards and notes it is one study, one dose, never replicated at scale. Malaria protocols used 10 mg per kilogram twice daily for three days alongside other antimalarials. Septic shock uses it intravenously. Small controlled trials exist in bipolar and depressed patients, and a phase 3 Alzheimer’s trial in 891 patients missed its primary endpoint. The rodent curve is the strangest part: memory improved from 0.005 up to 4 mg per kilogram with the peak at 4, the benefit vanished at 5, and 50 to 100 mg per kilogram caused impairment. The oddity Tony still cannot fully explain is that psychiatric trials used 15 mg and 8 mg a day as the placebo or low arm, while consumer products sit between 5 and 30 mg. A dose chosen because it should do nothing is the dose biohackers are taking, and yet people report effects at it.
Grading the claims
Tony’s scale runs A for proven in people, B for limited human data, C for animal or lab only, D for mechanism says so, and E for anecdote. Treating the blood disorder gets the A, since that is the approved use. Antimalarial, memory and cognition, mood and depression, and septic shock get B. Neuroprotection gets a C, along with anti-inflammatory, antimicrobial and antiviral, skin and photoaging, and longevity, all animal or lab work that Tony thinks likely translates because rats and humans handle microbes and oxidation similarly. Antioxidant effects and energy and fatigue improvement get D, on mechanism. Exercise performance gets E, and Tony flags that as odd: if the molecule is raising energy output in every cell, why are more people not reporting athletic benefits?
He is careful about the jump from mechanism to outcome. If a compound is an antioxidant, antioxidant benefits should follow, and yet beta-carotene, expected to cut cancer risk, raised lung cancer 18 to 26% in smokers. His explanation for failures like that and the Alzheimer’s miss is the single-molecule model of drug trials. The body runs on cofactors, and he believes drugs do too, so a compound that fails alone may work as part of a stack that mitigates its side effects or hits the same target through a second pathway. That is a belief, and he presents it as one.
What people say and the risk they ignore
The anecdotal reports rank energy first, then brain fog, focus, and mood. Tony reads one: fifteen years of supplements and nothing improved energy as much as methylene blue. His interpretation is the rate-limiting-step principle, the same reason vitamin C does more for someone deficient in it. That person probably had a real problem in the transport chain. Someone whose chain is fine may feel nothing and should look at a different pathway. He also reads a negative report, someone experiencing anhedonia and feeling emotionless early on, and notes that neither the dose nor what it was combined with was stated, which is the problem with most anecdotes.
Then the risk. Methylene blue is a monoamine oxidase inhibitor. Combine it with an SSRI, an SNRI, or other serotonergic drugs, recreational ones included, and it can trigger serotonin syndrome, which Tony describes as a prolonged physical anxiety attack, heart racing, a miserable feeling that lasts. Low serotonin brought to normal calms anxiety; serotonin pushed too high causes severe physical anxiety. Some people call it a harmless blue nootropic. Because of the MAOI activity, Tony says it has to be handled like a drug.
Cheat Sheet Pivot
What Tony reported and what the studies used. He does not state his own dose in the video.
- The approved antidote course is 1 to 2 mg per kilogram IV, repeatable once, capped at 7 mg per kilogram. The single memory trial used 280 mg orally, once. Nothing in the video is a daily human template.
- Tony started methylene blue roughly a decade ago after a doctor told him it was the single most powerful compound for delaying aging, and Coach Trevor called it one of the most underrated things in existence. He has used it on and off since, at doses he kept deliberately low out of concern for serotonin syndrome.
- He describes one episode where he raised the dose and combined it with something serotonergic, felt the early stages of serotonin syndrome, and has stayed low ever since.
- He has used it in the morning as an MAOI to extend the half-life of other compounds, and at night because he finds it calming, as long as nothing serotonergic is in the picture.
- He describes one higher-dose period, combined with other medications, during a viral illness he declines to name, and believes it contributed to a fast recovery after two weeks of being sick.
- His summary advice is to err on the side of caution and be hyper-aware of anything that touches serotonin.
Methylene blue’s entry alongside the rest of the nootropic catalog is in the Miracle Molecules Cheat Sheet. Tony’s later, deeper re-check of the human literature, including the G6PD contraindication and the serotonin syndrome case series, is in Methylene Blue for the Brain? What the Human Studies Actually Show. For the mitochondrial story in more depth, read Methylene Blue for Mitochondrial Function: The Original Nootropic Rediscovered.
Where the evidence stops
The strongest human evidence outside the approved use is one dose in 26 people, and the largest trial ever run, 891 Alzheimer’s patients, missed. Tony does not give up on the compound for that indication, but his reason is a belief about multi-pathway stacking rather than data. Longer human trials, dose-response curves, and testing across more doses and longer periods are all missing, and he says so.
What remains is a medically approved molecule, widely used in biohacking, that he has taken for a decade at low doses with a single scare. His verdict is that in a future where people had access to the full chemistry, methylene blue would be part of the daily multivitamin. That is his forecast, not a finding, and he labels it that way.
Keep going
For how Tony has run it day to day, read Methylene Blue: The Mitochondrial Nootropic Tony Runs Every Morning. New companion articles reach the tonyhuge.is email list first, and the nootropic archive is on tonyhuge.is.